The Ontario Institute for Cancer Research (OICR) in Toronto says it invested in three new Ontario companies aimed at bringing anti-cancer technologies to market. OICR previously provided seed funding for the three companies.
The three companies include:
– TORCell Therapeutics Inc. is a spin-off of OICR and University Health Network in Toronto. The company is developing an immunotherapy for the treatment of acute myeloid leukemia, involving use of a sub-population of the patient’s own cancer-killing T cells. The OICR funds will be used to prepare for the first human clinical trial, expected to begin in 2012.
– DLVR Therapeutics Inc., also a spin-off company from OICR and the University Health Network, is developing a nanotechnology-based delivery and targeting technology with the potential to deliver chemotherapeutics and small interfering RNA to cancer cells more safely and with greater impact and reduced side effects for cancer patients. The OICR proceeds are expected to accelerate further development of the technology.
– Harmonic Medical Inc. is building a tumor treatment system, invented by scientists at Sunnybrook Health Sciences Centre in Toronto and Brigham and Women’s Hospital in Boston, Massachusetts. Harmonic Medical uses ultrasound to precisely target and destroy cancer sites deep in the body to non-invasively destroy diseased tissue. It is used to ablate tumors with fewer side effects and complications than surgery. OICR’s investment will be used to complete prototype validation and prepare the technology to move into clinical trials.
Read more: Organic Nanoparticle in Development for Cancer Drug Delivery
Photo: Håkan Dahlström/Flickr
* * *
RSS - Posts
[…] i Science Business. You might also like this: Published in Silver & […]
[…] i Science Business. Share if you […]